Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernewsroom.regeneron.com
Regeneron Pharmaceuticals Inc. News Releases
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 144 followers
Latest posts
Last updated about 20 hours ago
Regeneron Announces Investor Conference Presentations
about 20 hours ago
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
2 days ago
36 abstracts to be presented across Regeneron -invented therapies, including first-time Phase...
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
10 days ago
New presentations include final 64-week results from the Phase 3 QUASAR trial...
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
13 days ago
Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter...
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
22 days ago
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery...
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
about 1 month ago
TARRYTOWN, N.Y. , Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
about 2 months ago
Approval based on global Phase 3 program in children demonstrating Dupixent significantly...
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
about 2 months ago
TARRYTOWN, N.Y. , Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
2 months ago
All three dose groups (50 mg, 100 mg and 200 mg) showed...
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
2 months ago
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation...
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
3 months ago
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and...
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
3 months ago
First and only FDA-approved treatment for RVO indicated for up to every...